{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:35:19Z","timestamp":1793144119874,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2016,11,29]],"date-time":"2016-11-29T00:00:00Z","timestamp":1480377600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s40265-016-0671-3","type":"journal-article","created":{"date-parts":[[2016,11,29]],"date-time":"2016-11-29T09:14:00Z","timestamp":1480410840000},"page":"1787-1792","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Etelcalcetide: First Global Approval"],"prefix":"10.1007","volume":"76","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,29]]},"reference":[{"issue":"2","key":"671_CR1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1517\/14728214.2015.1018177","volume":"20","author":"M Cozzolino","year":"2015","unstructured":"Cozzolino M, Tomlinson J, Walsh L, et al. Emerging drugs for secondary hyperparathyroidism. Expert Opin Emerg Drugs. 2015;20(2):197\u2013208.","journal-title":"Expert Opin Emerg Drugs."},{"issue":"5","key":"671_CR2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/sdi.12357","volume":"28","author":"M Rodriguez","year":"2015","unstructured":"Rodriguez M, Goodman WG, Liakopoulos V, et al. The use of calcimimetics for the treatment of secondary hyperparathyroidism: a 10 year evidence review. Semin Dial. 2015;28(5):497\u2013507.","journal-title":"Semin Dial."},{"key":"671_CR3","unstructured":"Amgen. European Commission approves Parsabiv\u2122 (etelcalcetide) for the treatment of secondary hyperparathyroidism in adults on hemodialysis [media release]. 11 Nov 2016. http:\/\/www.amgen.com ."},{"key":"671_CR4","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Parsabiv: etelcalcetide\u2014summary of opinion (initial authorisation). 2016. http:\/\/www.ema.europa.eu . Accessed 19 Oct 2016."},{"key":"671_CR5","unstructured":"Amgen. Amgen submits marketing authorization application for novel intravenous calcimimetic etelcalcetide (AMG 416) to the European Medicines Agency [media release]. 2 Sep 2015. http:\/\/www.amgen.com ."},{"key":"671_CR6","unstructured":"Amgen. Amgen provides update on status of Parsabiv\u2122 (etelcalcetide) New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) [media release]. 24 Aug 2016. http:\/\/www.amgen.com ."},{"key":"671_CR7","unstructured":"Ono Pharmaceutical. ONO submits manufacturing and marketing approval application in Japan for \u201cetelcalcetide hydrochloride\u201d (ONO-5163), a calcimimetic agent, for secondary hyperparathyroidism in patients on hemodialysis [media release]. 14 Jan 2016. http:\/\/www.ono.co.jp ."},{"key":"671_CR8","unstructured":"Ono Pharmaceutical. Ono enters into license agreement with KAI Pharmaceuticals, Inc. for KAI 4169 [media release]. 15 Sep 2011. http:\/\/www.ono.co.jp ."},{"key":"671_CR9","unstructured":"Amgen. Amgen completes acquisition of KAI Pharmaceuticals [media release]. 5 Jul 2012. http:\/\/www.amgen.com ."},{"issue":"2","key":"671_CR10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.113.204834","volume":"346","author":"S Walter","year":"2013","unstructured":"Walter S, Baruch A, Dong J, et al. Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther. 2013;346(2):229\u201340.","journal-title":"J Pharmacol Exp Ther."},{"issue":"5","key":"671_CR11","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/mol.115.098392","volume":"88","author":"ST Alexander","year":"2015","unstructured":"Alexander ST, Hunter T, Walter S, et al. Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action. Mol Pharmacol. 2015;88(5):853\u201365.","journal-title":"Mol Pharmacol."},{"issue":"1","key":"671_CR12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1471-2369-15-81","volume":"15","author":"S Walter","year":"2014","unstructured":"Walter S, Baruch A, Alexander ST, et al. Comparison of AMG 416 and cinacalcet in rodent models of uremia. BMC Nephrol. 2014;15(1):81.","journal-title":"BMC Nephrol."},{"issue":"2","key":"671_CR13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ndt\/gft417","volume":"29","author":"KJ Martin","year":"2014","unstructured":"Martin KJ, Bell G, Pickthorn K, et al. Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. Nephrol Dial Transplant. 2014;29(2):385\u201392.","journal-title":"Nephrol Dial Transplant."},{"key":"671_CR14","doi-asserted-by":"crossref","unstructured":"Shen J, Vick A, Pickthorn K, et al. The PK\/PD relationship of calcimimetic KAI-4169 following single-dose administration to healthy young males [abstract no. P1-236 ]. In: The Endocrine Society\u2019s 93rd Annual Meeting and Expo. 2011.","DOI":"10.1210\/endo-meetings.2011.PART1.P11.P1-236"},{"issue":"1","key":"671_CR15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ki.2013.289","volume":"85","author":"KJ Martin","year":"2014","unstructured":"Martin KJ, Pickthorn K, Huang S, et al. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Int. 2014;85(1):191\u20137.","journal-title":"Kidney Int."},{"issue":"Suppl 1","key":"671_CR16","doi-asserted-by":"crossref","first-page":"i462","DOI":"10.1093\/ndt\/gfw190.25","volume":"31","author":"K Yokoyama","year":"2016","unstructured":"Yokoyama K, Fukagawa M, Shigematsu T, et al. A novel intravenous calcimimetic, ONO-5163 (etelcalcetide): a multicenter, single and multiple dose study in Japanese hemodialysis patients with secondary hyperparathyroidism [abstract no. MP368]. Nephrol Dial Transplant. 2016;31(Suppl 1):i462.","journal-title":"Nephrol Dial Transplant."},{"issue":"10","key":"671_CR17","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/jcph.314","volume":"54","author":"J Shen","year":"2014","unstructured":"Shen J, Xiao J, Pickthorn K, et al. A pharmacokinetic\/pharmacodynamic model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects. J Clin Pharmacol. 2014;54(10):1125\u201333.","journal-title":"J Clin Pharmacol."},{"issue":"6","key":"671_CR18","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/jcph.460","volume":"55","author":"P Chen","year":"2015","unstructured":"Chen P, Melhem M, Xiao J, et al. Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis. J Clin Pharmacol. 2015;55(6):620\u20138.","journal-title":"J Clin Pharmacol."},{"key":"671_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0433-0","author":"R Subramanian","year":"2016","unstructured":"Subramanian R, Zhu X, Hock MB, et al. Pharmacokinetics, biotransformation, and excretion of [(14)C]etelcalcetide (AMG 416) following a single microtracer intravenous dose in patients with chronic kidney disease on hemodialysis. Clin Pharmacokinet. 2016. doi: 10.1007\/s40262-016-0433-0 .","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"671_CR20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ekir.2016.04.002","volume":"1","author":"KZ Edson","year":"2016","unstructured":"Edson KZ, Wu BM, Iyer A, et al. Determination of etelcalcetide biotransformation and hemodialysis kinetics to guide the timing of its dosing. Kidney International Reports. 2016;1(1):24\u201333.","journal-title":"Kidney International Reports."},{"issue":"8","key":"671_CR21","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1124\/dmd.115.068007","volume":"44","author":"R Subramanian","year":"2016","unstructured":"Subramanian R, Zhu X, Kerr SJ, et al. Nonclinical pharmacokinetics, disposition, and drug-drug interaction potential of a novel d-amino acid peptide agonist of the calcium-sensing receptor AMG 416 (etelcalcetide). Drug Metab Dispos. 2016;44(8):1319\u201331.","journal-title":"Drug Metab Dispos."},{"key":"671_CR22","unstructured":"Cunningham J, Trial Steering Committee. A long acting intravenous calcimimetic (AMG416) for secondary hyperparathyroidism (SHPT) in haemodialysed patients [abstract no. 15-LBA-3558]. In: 52nd ERA-EDTA Congress. 2015."},{"issue":"Suppl 1","key":"671_CR23","doi-asserted-by":"crossref","first-page":"i13","DOI":"10.1093\/ndt\/gfw122.03","volume":"31","author":"DA Bushinsky","year":"2016","unstructured":"Bushinsky DA, Block GA, Cheng S, et al. One year efficacy and safety of intravenous (IV) etelcalcetide (AMG 416) in patients on hemodialysis (HD) with secondary hyperparathyroidism (SHPT) [abstract no. SO030]. Nephrol Dial Transplant. 2016;31(Suppl 1):i13\u20134.","journal-title":"Nephrol Dial Transplant."},{"issue":"Suppl 1","key":"671_CR24","doi-asserted-by":"crossref","first-page":"i460","DOI":"10.1093\/ndt\/gfw190.18","volume":"31","author":"M Fukagawa","year":"2016","unstructured":"Fukagawa M, Yokoyama K, Shigematsu T, et al. Efficacy and safety of a novel intravenous calcimimetic, ONO-5163 (etelcalcetide) in Japanese hemodialysis patients with secondary hyperparathyroidism : results of a placebo controlled phase III study [abstract no. MP361]. Nephrol Dial Transplant. 2016;31(Suppl 1):i460.","journal-title":"Nephrol Dial Transplant."},{"key":"671_CR25","first-page":"B9","volume":"26","author":"K Martin","year":"2015","unstructured":"Martin K, Block G, Cheng S, et al. Comparison of the efficacy and safety of intravenous (IV) etelcalcetide (AMG 416) and oral cinacalcet (CIN) in patients on hemodialysis (HD) with secondary hyperparathyroidism (sHPT) [abstract no. SA-PO1115]. J Am Soc Nephrol. 2015;26:B9.","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"671_CR26","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1185\/03007995.2015.1031731","volume":"31","author":"G Bell","year":"2015","unstructured":"Bell G, Huang S, Martin KJ, et al. A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients. Curr Med Res Opin. 2015;31(5):943\u201352.","journal-title":"Curr Med Res Opin."},{"issue":"5","key":"671_CR27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000442754","volume":"42","author":"DA Bushinsky","year":"2015","unstructured":"Bushinsky DA, Block GA, Martin KJ, et al. Treatment of secondary hyperparathyroidism: results of a phase 2 trial evaluating an intravenous peptide agonist of the calcium-sensing receptor. Am J Nephrol. 2015;42(5):379\u201388.","journal-title":"Am J Nephrol."},{"key":"671_CR28","unstructured":"European Medicines Agency. Parsabiv: summary of product characteristics. 2016. http:\/\/www.ema.europa.eu . Accessed 28 Nov 2016."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0671-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0671-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0671-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T22:11:06Z","timestamp":1568585466000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0671-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,29]]},"references-count":28,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["671"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0671-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,29]]}}}